Nivolumab-Ipilimumab Increases Treatment-Free Survival in Advanced Melanoma
Source: Dermatology Advisor, August 2023
Patients with advanced melanoma receiving nivolumab in combination with ipilimumab as first-line treatment experience longer treatment-free survival than those receiving nivolumab or pembrolizumab monotherapy, according to a study published in JAMA Network Open.
Researchers in Canada conducted a multicenter cohort study among patients with advanced melanoma receiving first-line immune checkpoint inhibitor therapy (ICI) between August 2013 and May 2020. Patients received standard care or first-line ICI therapy with either nivolumab or pembrolizumab monotherapy or ipilimumab-nivolumab. The primary outcome was treatment-free survival.
Treatment-free survival was defined as the difference between the 36-month restricted mean survival time for 2 conventional survival endpoints. The first endpoint was the time from treatment initiation to ICI cessation, death, or censoring at last follow-up. The second endpoint was the time from treatment initiation to subsequent systemic anticancer therapy, death, or censoring at last follow-up.